ArticleThe American journal of pathology2009
Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo.
Article in The American journal of pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 56 citations in OpenAlex.
- Dietary Polyphenols Effects on Focal Adhesion Plaques and Metalloproteinases in Cancer Invasiveness.Biomedicines · 2024Review
- Regulation of ERα-dependent breast cancer metastasis by a miR-29a signaling.Journal of experimental & clinical cancer research : CR · 2023Article
- RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.Breast cancer research : BCR · 2021Article
- Epsins 1 and 2 promote NEMO linear ubiquitination via LUBAC to drive breast cancer development.The Journal of clinical investigation · 2021Article
- The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL.International journal of molecular sciences · 2020Review
- CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors.eLife · 2019Article
- RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.Journal of experimental & clinical cancer research : CR · 2019Review
- The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module.Cancer research · 2015Article
- In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: perspectives on cancer treatment.International journal of molecular sciences · 2015Review
- Sirt1-deficient mice have hypogonadotropic hypogonadism due to defective GnRH neuronal migration.Molecular endocrinology (Baltimore, Md.) · 2015Article
- Article
- CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling.Oncotarget · 2014Article
- Acetylation-defective mutant of Pparγ is associated with decreased lipid synthesis in breast cancer cells.Oncotarget · 2014Article
- Article
- ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation.Journal of cellular biochemistry · 2014Article
- Aberrant expression of NF-κB in liver fluke associated cholangiocarcinoma: implications for targeted therapy.PloS one · 2014Article
- Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer.Oncotarget · 2013Article
- Dachshund binds p53 to block the growth of lung adenocarcinoma cells.Cancer research · 2013Article
- TWIST1 associates with NF-κB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production.BMC biology · 2012Article
- MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells.Cancer science · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
The (HER2/Neu) ErbB2 oncogene is commonly overexpressed in human breast cancer and is sufficient for mammary tumorigenesis in transgenic mice. Nuclear factor (NF)-kappaB activity is increased in both human and murine breast tumors. The immune response to mammary tumorigenesis may regulate tumor progression. The role of endogenous mammary epithelial cell NF-kappaB had not previously been determined in immune-competent animals. Furthermore, the role of the NF-kappaB components, p50 and p65, in tumor growth was not known. Herein, the expression of a stabilized form of the NF-kappaB-inhibiting IkappaBalpha protein (IkappaBalphaSR) in breast tumor cell lines that express oncogenic ErbB2 inhibited DNA synthesis and growth in both two- and three-dimensional cultures. Either NF-kappaB inhibition or selective silencing of p50 or p65 led to a loss of contact-independent tumor growth in vitro. IkappaBalphaSR reversed the features of the oncogene-induced phenotype under three-dimensional growth conditions. The NF-kappaB blockade inhibited ErbB2-induced mammary tumor growth in both immune-competent and immune-deficient mice. These findings were associated with both reduced tumor microvascular density and a reduction in the amount of vascular endothelial growth factor. The expression of IkappaBalphaSR in breast cancer tumors inhibited angiogenesis. Thus, mammary epithelial cell NF-kappaB activity enhances ErbB2-mediated mammary tumorigenesis in vivo by promoting both growth and survival signaling via the promotion of tumor vasculogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.